In particular, he developed algebraic tools to solve tough problems such as differential equations, and he greatly extended the scope of the mathematical theory of symmetry known as representation ...

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device, after clinical trial data showed the treatment did not ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%.

Leading industry experts join the Vertex Chief Strategy Office to shape product innovation and strengthen global compliance strategies for customers KING OF PRUSSIA, Pa., April 10, 2025 (GLOBE ...

Symmetry Panoramic Tax-Managed Glb Eq Fd earns a Low Process Pillar rating. The largest detractor from the rating is the parent firm's five-year risk-adjusted success ratio of 38%. The measure ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and ...

Andreas Kluth is a Bloomberg Opinion columnist covering US diplomacy, national security and geopolitics. Previously, he was editor-in-chief of Handelsblatt Global and a writer for the Economist ...

The latest analyst rating for Vertex Pharmaceuticals (NASDAQ:VRTX) was provided by RBC Capital, and Vertex Pharmaceuticals maintained their sector perform rating. The last upgrade for Vertex ...

New Delhi [India], March 27: Axis Max Life Insurance Ltd., formerly known as Max Life Insurance Company Ltd. ('Axis Max Life'/ 'Company'), has redefined Out-of-Home (OOH) advertising with an ...